Reports

Sale

Granulomatosis with Polyangiitis Treatment Market

Global Granulomatosis with Polyangiitis Treatment Market Share, Size, Research: By Drug Class: Steroids, Immunosuppressant, Others; By Route of Administration: Oral, Intravenous, Others; By Distribution Channels: Hospital Pharmacies, Others; Regional Analysis; Competitive Landscape: Industry Events and Developments; 2024-2032

Global Granulomatosis with Polyangiitis Treatment Market Outlook

The global granulomatosis with polyangiitis treatment market size is expected to grow in the forecast period of 2024-2032 at a CAGR of 4.90%.  

 

granulomatosis with polyangiitis treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Usage of Immunosuppressants to Augment the Global Granulomatosis with Polyangiitis Treatment Industry

Immunosuppressants for the treatment of granulomatosis with polyangiitis are gaining traction in the healthcare industry owing to the high response rate of this medication. Immunosuppressants such as cyclophosphamide with prednisone are widely used in the treatment of this disease as they pose less chance of fatality during the treatment. 

 

Such immunosuppressants are consumed orally which is a major advantage of this medication amidst the changing patient preference towards minimally invasive treatment procedures. Methotrexate and azathioprine are some other examples of immunosuppressants which calm down the immune system of body, thereby, keeping the disease under control. Therefore, the anticipated increase in the demand for immunosuppressants are likely to aid the segment’s growth in the coming years. 

 

North America Leads the Market for Granulomatosis with Polyangiitis Treatment 

Countries such as the United States are high healthcare spenders globally. The regulations of the government encouraging the development of therapeutics and diffusing knowledge about this disorder are propelling the market growth. In addition to this, the growing FDA-approvals of immunosuppressants and drugs are further expanding the opportunities for the global granulomatosis with polyangiitis treatment market. 

 

Market Segmentation

Granulomatosis with polyangiitis is defined as a medical condition which causes inflammation of blood vessels. Body parts of humans affected by this disease include ears, nose, and kidney, among others. This disease is prevalent among children, adults and geriatrics, and granulomatosis with polyangiitis treatment is aimed at diagnosis and various medications.

 

granulomatosis with polyangiitis treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on drug class, the market can be segmented into:

  • Steroids
  • Immunosuppressant
  • Others

 

By route of administration, the market has been divided into:

  • Oral
  • Intravenous
  • Others

 

On the basis of distribution channel, the granulomatosis with polyangiitis treatment market has been categorised into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

 

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

granulomatosis with polyangiitis treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Escalating Prevalence to Boost the Growth of the Granulomatosis with Polyangiitis Treatment Industry

The escalating prevalence of granulomatosis with polyangiitis owing to the increasing cases of immunological disorders caused by the sedentary lifestyles led by the working class population is driving the global granulomatosis with polyangiitis treatment market. This disease causes severe symptoms such as chest pain, tiredness, nosebleed, loss of appetite, and weight-loss, among others, which compel the victims to go for check-ups. This factor is further invigorating the market growth. 

 

Over the forecast period, the anticipated increase in the research and development activities by major biopharmaceutical companies aimed towards developing effective therapeutics to counter this disorder are likely to lead to improved medications. Moreover, the market is anticipated to be aided by organised X-rays, CT scans, and MRI in modern hospitals which is bolstering the diagnosis process for timely treatment of this condition. Furthermore, the market is likely to be navigated by the increasing geriatric population, coupled with the favourable reimbursement policies of the government. 

 

Key Players in the Global Market for Granulomatosis with Polyangiitis Treatment

The report gives a detailed analysis of the following key players in the global granulomatosis with polyangiitis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

 

  • Genentech, Inc.
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Others

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Route of Administration
  • Distribution Channels
  • Region
Breakup by Drug Class
  • Steroids
  • Immunosuppressant
  • Others
Breakup by Route of Administration
  • Oral
  • Intravenous
  • Others
Breakup by Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Genentech, Inc.
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface 
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions   
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Opportunities and Challenges in the Market
8    Global Granulomatosis with Polyangiitis Treatment Market Analysis
    8.1    Key Industry Highlights
    8.2    Global Granulomatosis with Polyangiitis Treatment Historical Market (2018-2023) 
    8.3    Global Granulomatosis with Polyangiitis Treatment Market Forecast (2024-2032)
    8.4    Global Granulomatosis with Polyangiitis Treatment Market by Drug Class
        8.4.1    Steroids
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Immunosuppressant
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Others
    8.5    Global Granulomatosis with Polyangiitis Treatment Market by Route of Administration
        8.5.1    Oral
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Intravenous
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Others
    8.6    Global Granulomatosis with Polyangiitis Treatment Market by Distribution Channels
        8.6.1    Hospital Pharmacies
            8.6.1.1    Historical Trend (2018-2023)
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Retail Pharmacies
            8.6.2.1    Historical Trend (2018-2023)
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Others
    8.7    Global Granulomatosis with Polyangiitis Treatment Market by Region     
        8.7.1    North America
            8.7.1.1    Historical Trend (2018-2023) 
            8.7.1.2    Forecast Trend (2024-2032)
        8.7.2    Europe
            8.7.2.1    Historical Trend (2018-2023) 
            8.7.2.2    Forecast Trend (2024-2032)
        8.7.3    Asia Pacific
            8.7.3.1    Historical Trend (2018-2023) 
            8.7.3.2    Forecast Trend (2024-2032)
        8.7.4    Latin America
            8.7.4.1    Historical Trend (2018-2023) 
            8.7.4.2    Forecast Trend (2024-2032)
        8.7.5    Middle East and Africa
            8.7.5.1    Historical Trend (2018-2023) 
            8.7.5.2    Forecast Trend (2024-2032)
9    North America Granulomatosis with Polyangiitis Treatment Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Granulomatosis with Polyangiitis Treatment Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5   Others
11    Asia Pacific Granulomatosis  with Polyangiitis Treatment Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Granulomatosis with Polyangiitis Treatment Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Granulomatosis with Polyangiitis Treatment Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Genentech, Inc.
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    GlaxoSmithKline plc.
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Teva Pharmaceutical Industries Ltd.
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Pfizer Inc.
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
            15.2.5    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Granulomatosis with Polyangiitis Treatment Market: Key Industry Highlights, 2018 and 2032
2.    Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Drug Class (USD Million), 2018-2023
3.    Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
4.    Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
5.    Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
6.    Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
7.    Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
8.    Global Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
9.    Global Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10.    North America Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11.    North America Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Europe Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Europe Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Asia Pacific Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Asia Pacific Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Latin America Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Latin America Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Middle East and Africa Granulomatosis with Polyangiitis Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19.    Middle East and Africa Granulomatosis with Polyangiitis Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20.    Global Granulomatosis with Polyangiitis Treatment Market Structure.

Key Questions Answered in the Report

The market is estimated to grow at a CAGR of 4.90% between 2024 and 2032.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The growing rapid advancements in healthcare infrastructure is likely to be a key trend in the market.

The major drivers of the market include the increasing cases of immunological disorders, severe symptoms of the disease, and improvements in medications. 

Steroids, and immunosuppressants, among others are the different segments based on drug class.

Oral, and intravenous, among others are the different segments based on route of administration.

Hospital pharmacies, and retail pharmacies, among others are the different distribution channels included in the market report. 

The major players in the industry are Genentech, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., and Pfizer Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER